Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
pletion of clinical studies the ability of ProMetic to take advantageof business opportunities in the pharmaceutical industry uncertaintiesrelated to the regulatory process and general changes in economicconditions. You will find a more detailed assessment of the risks thatcould cause actual events or results to materially differ from our currentexpectations on page 21 of ProMetic's Annual
Date:4/23/2008